Shares of Nuformix plc (LON:NFX – Get Free Report) traded down 6.9% during trading on Wednesday . The company traded as low as GBX 0.15 and last traded at GBX 0.15. Approximately 6,983,824 shares were traded during trading, a decline of 78% from the average daily volume of 31,040,061 shares. The stock had previously closed at GBX 0.16.
Nuformix Price Performance
The company has a market capitalization of £3.89 million, a price-to-earnings ratio of -5.09 and a beta of 1.54. The stock has a 50 day simple moving average of GBX 0.18 and a two-hundred day simple moving average of GBX 0.20.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings results on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
- Meta’s AI Spending Problem Just Found a BlackRock Solution
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
